Browse drugs

…, nivolumab-(n=15), and nivolumab+relatlimab (n=14) followed by nivolumab+relatlimab in first-line advanced melanoma. Overall primary obj…

…ously evaluated in patients with advanced melanoma treated with nivolumab plus ipilimumab. This analysis compared TFS for nivolumab plus …

…TEZO, atezolizumab; BINI, binimetinib; COBI, cobimetinib; ENCO, encorafenib; ESS, effective sample size; DAB, dabrafenib; NIVO, nivolumab; …

…city, with G3/4 events reported in 22% compared with 14% in the nivolumab monotherapy arm. An update presented at the European Society of…

… be enrolled in the first stage. If ≥2 patients respond to NIVO+RELA, the study will continue enrollment for a total of 20 patients.…

…t-remission, one of whom achieved CR after salvage therapy with nivolumab. Among the 4 patients who were treated with relatlimab and nivo…

…(NIVO+RELA) to BRAF/MEK inhibitors, we compared its efficacy to dabrafenib+trametinib (DAB+TRAM), encorafenib+binimetinib (ENCO+BINI), vem…

… followed by rela/nivo (arm B, N=71), and anti-PD-1 followed by rela/nivo (arm C, N=79). The study assessed the impact of treatment seque…

…, Lao CD, De Menezes JJ, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med . 2022;386:24–34. …

…114 male and 50 female (unspecified 17). The ICIs involved were nivolumab (n=68), pembrolizumab (n=51), ipilimumab (n=35), atezolizumab (…

…II disease (93%). 55% (42/76) were treated with Ipilimumab plus Nivolumab (I/N), 41% (31/76) anti-PD1 monotherapy (PD1) and 4% (3/76) Niv…

…2 and Flu 30 mg/m2 x 4 days, followed by a one-time infusion of IMA203 (1-10x 109 TCR T cells), and low-dose IL-2 (1 M IU QD x5 days, …